Article
Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.
Journal of virology - 1 Apr 1995
Patick A K, Rose R, Greytok J, Bechtold C M, Hermsmeier M A, Chen P T, Barrish J C, Zahler R, Colonno R J, Lin P F
Abstract excerpt
Development of viral resistance to the aminodiol human immunodeficiency virus (HIV) protease inhibitor BMS 186,318 was studied by serial passage of HIV type 1 RF in MT-2 cells in the presence of increasing concentrations of compound. After 11 passages, an HIV variant that showed a 15-fold increase in 50% effective dose emerged. This HIV variant displays low-level cross-resistance to the C2 symmetric inhibitor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.